登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 大股东持股的基本情况：截至本公告披露日，持股5%以上股东上海国盛（集团）有限公司（以下简 称"国盛集团"）持有上海建工集团股份有限公司（以下简称"公司"）股份1,301,300,000股，占公司总股 本的比例为14.64%。上述股份来源于公司控股股东上海建工控股集团有限公司无偿划转及后续公司资 本公积转增股本取得。 ● 减持计划的主要内容：国盛集团计划自本公告披露之日起15个交易日后的3个月内（即2026年3月3 日-2026年6月2日）以集中竞价交易方式减持其所持有的公司股份数量不超过88,859,300股（不超过公司 总股本的1.00%）；以大宗交易方式减持其所持有的公司股份数量不超过177,718,700股（不超过公司总 股本的2.00%）。若此期间公司发生转增股本、增发新股或配股、股权激励、回购等股本变动事项，减 持股份比例保持不变，减持股份数量将进行相应调整。 一、减持主体的基本情况 ■ 上 ...

Core Viewpoint - The company, Guangdong Shengyi Technology Co., Ltd., forecasts a significant increase in net profit for the year 2025, with expected growth rates between 87% to 98% compared to the previous year [1][3]. Financial Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company ranging from 3.25 billion to 3.45 billion yuan for the year 2025, which represents an increase of 1.51133 billion to 1.71133 billion yuan year-on-year [3][4]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between 3.08 billion and 3.28 billion yuan, reflecting an increase of 1.40490 billion to 1.60490 billion yuan compared to the previous year [3][4]. Previous Year’s Financial Data - In the previous year, the total profit was 2.06793 billion yuan, with a net profit attributable to shareholders of the parent company at 1.73867 billion yuan, and a net profit excluding non-recurring gains and losses at 1.67510 billion yuan [4]. Reasons for Profit Increase - The increase in profit is attributed to a rise in sales volume of copper-clad laminates and an increase in revenue from these products, alongside continuous optimization of product structure to enhance gross margins [4]. - The subsidiary, Shengyi Electronics Co., Ltd., has focused on high-end market segments, increased R&D investment, and improved production capacity, which has strengthened the company's competitive advantage in the mid-to-high-end market, leading to substantial growth in revenue and net profit [4].

Core Viewpoint - The company, Kangxin New Materials Co., Ltd., is forecasting a significant net loss for the year 2025, continuing a trend of financial difficulties from the previous year [2][4]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of -394 million yuan for the year 2025 [2]. - The forecasted net profit, excluding non-recurring gains and losses, is projected to be -399.2 million yuan [3]. - The performance forecast period is from January 1, 2025, to December 31, 2025 [2]. Group 2: Previous Year Comparison - In the previous year, the net profit attributable to shareholders was -333.63 million yuan, and the net profit after excluding non-recurring items was -336.97 million yuan [4]. - The earnings per share for the previous year were -0.25 yuan [5]. Group 3: Reasons for Expected Loss - The primary reasons for the anticipated loss in 2025 include a continued adjustment in the supply and demand of the container market, leading to a decline in both sales prices and volumes [6]. - The average sales price of container floors is expected to decrease by approximately 28% compared to 2024, with a sales volume decline of about 18% [6]. - Despite efforts to improve production efficiency and increase self-produced output by approximately 245%, the overall market price decline has resulted in reduced sales revenue and increased losses [6].

重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 （一）经公司自查，公司日常经营活动正常，市场环境、行业政策没有发生 重大调整，内部生产经营 秩序正常，不存在应披露而未披露的重大信息。 （二）经公司自查，并书面征询公司控股股东广西正和实业集团有限公司（以下简称"广西正和"）和实 际控制人Hui Ling(许玲），截至本公告披露日，公司控股股东广西正和和实际控制人Hui Ling(许玲）均 不存在筹划影响公司股票异常波动的重大事项，不存在应披露而未披露的重大信息，包括但不限于重大 资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和资产注入等重大事项。 （三）公司未发现对公司股票交易价格可能产生重大影响的媒体报道或市场 传闻，除公司已披露信息 外，不存在其他应披露而未披露的重大信息。 （四）经公司核实，公司未发现其他可能对公司股价产生较大影响的重大事 件，公司控股股东、实际 控制人以及公司董事、监事、高级管理人员在本次股票 交易异常波动期间均未有买 ...

Core Viewpoint - The company expects a negative net profit for the fiscal year 2025, with a significant increase in losses compared to the previous year [1][2]. Financial Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 - The expected net profit is projected to be negative, with specific financial data presented in ten-thousands (万元) [1]. Communication with Auditors - The financial data related to this performance forecast has not been audited by the accounting firm, but the company has had preliminary discussions with them, and there are no significant disagreements regarding the forecast [1]. Reasons for Performance Changes - The prolonged suspension of operations at the Jinfo Lead-Zinc Mine due to the expiration of the mining license has led to a significant decrease in self-produced zinc concentrate, increasing the proportion of raw materials purchased externally - The overall tight supply of zinc concentrate in the market in 2025 has resulted in a rise in procurement prices, causing a substantial decline in the gross profit of zinc products - Losses from associated enterprises have led to a decrease in recognized investment income year-on-year - Tax payments made by subsidiaries and penalties for over-extraction at three subsidiaries have reduced the current net profit [1]. Summary of Losses - The combined reasons have resulted in a negative net profit attributable to shareholders of the listed company, with an increase in losses compared to the previous year [2].

Group 1 - The company expects a significant decline in net profit for the year 2025, projecting a decrease of over 50% compared to the previous year [1][2] - The performance forecast period is from January 1, 2025, to December 31, 2025, with the net profit expected to be positive but substantially lower [1] - The decline in performance is attributed to a sluggish market and intense competition in the taurine market, leading to a decrease in both the sales volume and prices of the main product, taurine [2] Group 2 - The performance forecast has not been audited by the accounting firm, and the final financial data will be confirmed in the annual report for 2025 [1][3] - Initial communication regarding the performance forecast has taken place with the annual audit accounting firm, but specific data will depend on the final audit results [1][3]

Group 1 - The company, Tianjin Lisheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its drug Aminophylline Tablets (0.1g) to pass the consistency evaluation of quality and efficacy for generic drugs [2] - The drug is classified as a chemical drug and is produced by Tianjin Lisheng Pharmaceutical Co., Ltd. The original drug approval number is Guoyao Zhunzi H12020118 [2] - Aminophylline Tablets are indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and can also be used for asthma caused by cardiogenic pulmonary edema [3] Group 2 - The approval of the drug enhances its market competitiveness for the company [4] - The sales performance of pharmaceutical products may be influenced by changes in the market environment, leading to significant uncertainty [4]

Group 1 - The company expects a negative net profit for the fiscal year 2025, covering the period from January 1, 2025, to December 31, 2025 [1] - The preliminary financial data for the profit forecast has not been audited by the accounting firm, but there were preliminary communications regarding the profit forecast with the auditing firm, and no significant disagreements were reported [1][2] Group 2 - The decline in performance is attributed to the impact of downstream industries, where both the volume and price of refractory materials for glass and cement kilns have decreased, leading to a contraction in gross profit margins [2] - The price of refractory materials for the steel industry has further declined, resulting in a decrease in the company's overall gross margin compared to the same period last year [2] - Due to industry cycle adjustments, the company has experienced slower-than-expected collection of accounts receivable, with an increasing trend in the aging distribution towards the medium to long-term range, prompting an increase in credit impairment losses [2]

Group 1 - The company expects a negative net profit for the fiscal year 2025, with specific figures not disclosed [2][4] - The decline in net profit is attributed to the ongoing downturn in the real estate market, leading to decreased sales of plastic pipes [4] - Despite the negative net profit, there is an expected year-on-year increase in net profit due to lower product costs, improved gross margin, reduced credit impairment provisions, and decreased sales and management expenses [4][5] Group 2 - The company has communicated with its accounting firm regarding the earnings forecast, and there are no disagreements on this matter [3] - The impact of non-recurring gains and losses on the net profit is estimated to be between 12 million to 15 million RMB [5] - The earnings forecast data is preliminary and has not been audited by the accounting firm, with final figures to be confirmed in the annual report [6] Group 3 - The company has recognized several related party transactions for the fiscal year 2025, including purchases from related entities and payment of utility fees on behalf of related individuals [24][26] - The total amount for related party transactions includes approximately 9.84 million RMB for mold and copper parts, 5.98 million RMB for raw materials, and utility fees totaling about 2.25 million RMB [26][30] - The board of directors has approved these related party transactions, ensuring compliance with relevant regulations and confirming that they do not adversely affect the company's financial status or independence [28][35]

一、获得补助的基本情况 上海三友医疗器械股份有限公司（以下简称"公司"）于近期收到政府补助合计130.00万元，占公司2024 年度经审计归属上市公司股东的净利润的比例为11.34%。上述政府补助属于与收益相关的政府补助。 证券代码：688085 证券简称：三友医疗 公告编号：2026-003 上海三友医疗器械股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海三友医疗器械股份有限公司董事会 2026年1月30日 二、补助的类型及对公司的影响 公司根据《企业会计准则第16号一一政府补助》等相关规定，确认上述事项并划分补助类型。上述政府 补助未经审计，具体的会计处理以及对公司相关年度损益的影响情况最终以审计机构年度审计确认后的 结果为准。敬请广大投资者注意投资风险。 特此公告。 ...